PROTAC/分子胶药物研发服务
PROTAC分子DMPK评价常见问题与解决方案：
时间：2022-08-22
来源：澳门永利welcome
分享：
【摘要】：
| DMPK | Issue | Recommendation |
| Solubility | Insoluable | Simulated fluid replace PBS buffer |
| Permeability | Poor recovery | Addition of BSA,FBS |
| Transporter | Substrate, or inhibitor | Specific transporter, hMDR1 Knockin MDCKll Cells Or, hBCRP Knockin MDCKll Cells |
| Bioanalysis | Unstable | Deactivate enzyme in plasma or blood immediately |
| Bioanalysis | Non specific binding | Detergent |
| Bioanalysis | Fragment inLs-MS ion source | Optimized MS condition |
| Metabolism | Diverse metabolism | Comprehensive metabolism system: microsome, hepatocyte, S9，cytosol；AO,UGT activity; CYP phenotyping |
| PPB | Unstable | Enzyme inhibitor |
| In vivo PK | Low bioavailability | No fasting |
媒体联络方式vivapr@vivabiotech.com
联系我们
Copyright © 澳门永利welcome All Rights Reserved. 沪ICP备19036061号